ArticleCureus2025
Mean Corpuscular Volume Is Not a Reliable Predictor of Iron Deficiency in Patients With Chronic Kidney Disease: A Post-Hoc Analysis of the BRIGHTEN Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in mean corpuscular volume after erythropoiesis-stimulating agent treatment are associated with renal outcomes in non-dialysis-dependent chronic kidney disease.Clinical and experimental nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Timely diagnosis of iron deficiency is crucial for managing anemia in patients with non-dialysis-dependent chronic kidney disease (ND-CKD). However, iron status results are not always immediately available. We aimed to examine the performance of mean corpuscular volume (MCV) in diagnosing iron deficiency as a primary objective and of iron status in predicting the onset of iron deficiency as a secondary objective. Methods This retrospective cohort study included adult patients with ND-CKD from the BRIGHTEN (oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa) trial (enrolled from June 2014 to September 2016) in Japan who were started on darbepoetin-alpha for renal anemia and patients who were not started on iron supplementation during weeks 0-24. Diagnostic performance analysis assessed the MCV at week 24 and changes in MCV from week 12 to 24 for diagnosing iron deficiency (ferritin < 100 ng/mL) at week 24, using receiver operating characteristic curves, area under the curve (AUC), sensitivity, and specificity. For the patients without iron deficiency at week 12, ferritin levels at week 12 were assessed by predictive performance analysis to predict new-onset iron deficiency at week 24. Results A total of 796 participants were included in the diagnostic performance analysis (mean age, 70.0 years; mean estimated glomerular filtration rate, 19.2 mL/min/1.73 m²), and 338 were included in the predictive performance analysis. Diagnostic performance analysis revealed an AUC for MCV of 0.55 (95% confidence interval (CI), 0.51-0.59); for MCV changes, it was 0.52 (95% CI, 0.48-0.57). Prognostic performance analysis revealed that ferritin at week 12 demonstrated an AUC of 0.77 (95% CI, 0.67-0.86), with a sensitivity of 83% and a specificity of 66% at a cutoff of 131.5 ng/mL. Conclusion Neither MCV nor the changes in MCV could reliably diagnose iron deficiency in patients with ND-CKD. Ferritin level < 130 ng/mL could predict new-onset iron deficiency within 12 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.